Current Report Filing (8-k)
22 März 2021 - 11:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 19, 2021 ( March 19, 2021)
LUCKWEL
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-187874
|
|
46-1660653
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
125
Cambridge Park Drive, Suite 301,Cambridge
|
|
MA
02140
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, include area code +1 (617) 430 5222
245
First Street, Suite 1800, Cambridge, MA 02142
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01 Entry into a Material Definitive Agreement.
On
March 19, 2021, our Chief Executive Officer, Mr. Kingrich Lee executed a Deed of Gift to irrevocably and unconditionally give,
transfer and assign, by way of gift, without limitation or restriction, to Luckwel Pharmaceuticals, Inc. (the “Company”)
all of his right, title and interest in, arising from and to the following drug programs:
|
Program
Code
|
|
Description
|
|
|
|
|
|
KL-2118
|
|
Candidate
drug to be developed into orally disintegrating tablets (ODT) to treat Type 2 diabetes.
|
|
|
|
|
|
KL-2119
|
|
Candidate
drug to be developed into an oral formulation treatment of HIV
|
|
|
|
|
|
KL-2120
|
|
Candidate
drug to be developed into a liquid injection for the treatment of rheumatoid arthritis.
|
The
foregoing description of the Deed of Gift does not purport to be complete and is qualified in its entirety by reference to the
Deed of Gift, which is attached to this Current Report on Form 8-K as Exhibit 10.1.
Item
9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
LUCKWEL PHARMACEUTICALS INC.
|
|
|
|
Date: March 19, 2021
|
|
/s/ Kingrich Lee
|
|
Name:
|
Kingrich Lee
|
|
Title:
|
Chief Executive Officer and Chief Financial Officer
|
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
Echtzeit-Nachrichten über Luckwel Pharmaceuticals Inc (GM) (OTCMarkets): 0 Nachrichtenartikel
Weitere Luckwel Pharmaceuticals Inc. News-Artikel